Willingdon Wealth Management’s AstraZeneca AZN Stock Holding History

Willingdon Wealth Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-90	Closed	-$9K	–	301
2019 Q4	$9K	Buy	90 +88	+4,400%	+$8.29K	﹤0.01%	246
2019 Q3	$0	Hold	2	–	–	﹤0.01%	503
2019 Q2	$0	Sell	2 -25	-93%	-$1.96K	﹤0.01%	307
2019 Q1	$2K	Buy	27 +26	+2,600%	+$2.05K	﹤0.01%	301
2018 Q4	$0	Sell	1 -14	-93%	-$1.09K	﹤0.01%	341
2018 Q3	$1K	Buy	+15	New	+$1.14K	﹤0.01%	384
2017 Q3	–	Sell	-45,766	Closed	-$3.12M	–	295
2017 Q2	$3.12M	Sell	45,766 -43,448	-49%	-$2.84M	1.24%	22
2017 Q1	$5.56M	Buy	89,214 +44,111	+98%	+$2.57M	2.25%	6
2016 Q4	$2.46M	Buy	+45,103	New	+$2.56M	1.16%	27

Other funds holding AZN

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Willingdon Wealth Management's AZN Position: Q1 2020 in Review

Willingdon Wealth Management sold out of AstraZeneca (AZN) in Q1 2020, closing a stake of 90 shares — an estimated $9K sold.

Willingdon Wealth Management first reported a position in AZN in Q4 2016 and held it in 9 quarters. The position peaked at $5.56M in Q1 2017. 603 funds tracked by Wall St. Rank hold AZN as of Q1 2020.

Willingdon Wealth Management reported no remaining AstraZeneca position as of Q1 2020 after selling out during the quarter.
Willingdon Wealth Management sold 90 AstraZeneca shares in Q1 2020, an estimated $9K.
Willingdon Wealth Management first reported a position in AstraZeneca in Q4 2016 and held it in 9 quarters.
Willingdon Wealth Management's AstraZeneca position peaked at $5.56M in Q1 2017.
603 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2020.

Based on Willingdon Wealth Management's 13F filing for Q1 2020, filed 21 Apr 2020.